Cankaya Rohat, Kleiner Pit Leonard, Hilke Franz Joachim, Moritz Rose, Eigentler Thomas, Schlaak Max, Dobos Gabor
Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Skin Cancer Centre, Charité - Universitätsmedizin Berlin, Berlin, Germany.
J Dtsch Dermatol Ges. 2025 Jul;23(7):822-830. doi: 10.1111/ddg.15702. Epub 2025 May 30.
Primary cutaneous B cell lymphomas (CBCL) are chronic diseases with frequent relapses. Time to next treatment (TTNT) is an endpoint reflecting clinical benefit of treatments including patient perspectives. The objectives were to evaluate clinical characteristics, survival, prognosis and TTNT in CBCL.
In this monocentric study, clinical data were extracted between 1998 and 2022. TTNT were calculated. Univariate and multivariate analyses were conducted.
Altogether, 46 patients with follicle center lymphoma (pcFCL), 41 with marginal zone lymphoproliferative disorder (pcMZLPD) and 11 with diffuse large B-cell lymphoma, leg type (DLBCL-LT) were identified. 26% of pcFCL patients relapsed frequently. The 5-year relapse-free survival was 71%, 87% and 23% in pcFCL, pcMZLPD and DLBCL-LT, respectively. In pcFCL and pcMZLPD, skin-directed treatments, such as excision or intralesional triamcinolone, performed best based on TTNT, while chemotherapy achieved a mean TTNT of 38 months in DLBCL-LT. In multivariate analysis of all patients, leg involvement was significantly associated with a decreased TTNT of the first treatment, while comorbidities were associated with an increased TTNT.
DLBCL-LT had the worst survival. Skin-directed treatments tend to achieve higher TTNT in pcFCL and pcMZLPD, while systemic treatments had higher TTNT in DLBCL-LT.
原发性皮肤B细胞淋巴瘤（CBCL）是一种易复发的慢性疾病。下次治疗时间（TTNT）是一个反映包括患者观点在内的治疗临床获益的终点指标。本研究旨在评估CBCL的临床特征、生存率、预后及TTNT。
在这项单中心研究中，提取了1998年至2022年期间的临床数据。计算TTNT，并进行单因素和多因素分析。
共纳入46例滤泡中心淋巴瘤（pcFCL）患者、41例边缘区淋巴增生性疾病（pcMZLPD）患者和11例腿部型弥漫性大B细胞淋巴瘤（DLBCL-LT）患者。26%的pcFCL患者频繁复发。pcFCL、pcMZLPD和DLBCL-LT的5年无复发生存率分别为71%、87%和23%。在pcFCL和pcMZLPD中，基于TTNT，手术切除或病灶内注射曲安奈德等皮肤定向治疗效果最佳，而化疗在DLBCL-LT中的平均TTNT为38个月。在所有患者的多因素分析中，腿部受累与首次治疗的TTNT降低显著相关，而合并症与TTNT增加相关。
DLBCL-LT的生存率最差。皮肤定向治疗在pcFCL和pcMZLPD中往往能获得更高的TTNT，而全身治疗在DLBCL-LT中具有更高的TTNT。
